Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO6870810 in RR-AML and MDS
NCT02308761Phase 1Completed
- Sponsor
- Roche
- Start
- Nov 2014
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RO-6870810 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Roche. Primary endpoints: Percentage of Participants With Dose-Limiting Toxicities at Cycle 1, Maximum Tolerated Dose at Cycle 1 and 1 more. Started Nov 2014; status: completed.
02
Drugs
RO-6870810
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02308761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02308761.